The invention relates to medicine and specifically to methods for treating recurring forms of diseases related to the family of herpes viruses. A method for treating recurring diseases of the skin and mucous membranes caused by HSV-1 and HSV-2 involves applying a preparation to an affected area, said preparation including a base containing 0.5% or 1% of an active substance, namely a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula (I): where X is Na, K, NH.sub.4; the preparation is applied twice daily for 3-5 days and, should prodromes appear, a second course of treatment is carried out, in which the preparation is applied 1-2 times daily for 2-3 days; the base containing the active substance can be in the form of a cream, an ointment, a gel, a suspension, suppositories, a patch or a film. Carrying out the second course of treatment provides a sharp increase in therapeutic efficacy, even to the extent of preventing relapse over a prolonged period of observation as a result of the effect of the preparation, upon reuse, on the viruses persisting in nerve cells.

The invention relates to medicine and specifically to methods for treating recurring forms of diseases related to the family of herpes viruses. A method for treating recurring diseases of the skin and mucous membranes caused by HSV-1 and HSV-2 involves applying a preparation to an affected area, said preparation including a base containing 0.5% or 1% of an active substance, namely a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula (I): where X is Na, K, NH.sub.4; the preparation is applied twice daily for 3-5 days and, should prodromes appear, a second course of treatment is carried out, in which the preparation is applied 1-2 times daily for 2-3 days; the base containing the active substance can be in the form of a cream, an ointment, a gel, a suspension, suppositories, a patch or a film. Carrying out the second course of treatment provides a sharp increase in therapeutic efficacy, even to the extent of preventing relapse over a prolonged period of observation as a result of the effect of the preparation, upon reuse, on the viruses persisting in nerve cells.

A topical burn cream includes zinc oxide in an amount equal to about 72 percent by weight; sulfanilamide in an amount equal to about 18 percent by weight; and iodine in an amount equal to about 0.09 percent by weight.

A topical burn cream includes zinc oxide in an amount equal to about 72 percent by weight; sulfanilamide in an amount equal to about 18 percent by weight; and iodine in an amount equal to about 0.09 percent by weight.

Methods for targeting apurinic/apyrimidinic endonuclease1/redox effector factor 1 (APE1/Ref-1) are disclosed. More particularly, methods for inhibiting APE1/Ref-1 and hypoxia-mediated signaling for decreasing survival and invasion of tumor cells exposed to hypoxic conditions are disclosed.

Methods for targeting apurinic/apyrimidinic endonuclease1/redox effector factor 1 (APE1/Ref-1) are disclosed. More particularly, methods for inhibiting APE1/Ref-1 and hypoxia-mediated signaling for decreasing survival and invasion of tumor cells exposed to hypoxic conditions are disclosed.

Methods for targeting apurinic/apyrimidinic endonuclease1/redox effector factor 1 (APE1/Ref-1) are disclosed. More particularly, methods for inhibiting APE1/Ref-1 and hypoxia-mediated signaling for decreasing survival and invasion of tumor cells exposed to hypoxic conditions are disclosed.

Described herein are pharmaceutical compositions capable of inhibiting vesicle formation and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat pathogenic infections.

The present disclosure provides methods for treating chronic lymphocytic leukemia (CLL) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC 105P.

The present disclosure provides methods for treating chronic lymphocytic leukemia (CLL) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC 105P.